Intravenous anti-D as a treatment for immune thrombocytopenic purpura (ITP) during pregnancy.
This pilot study assessed the safety and efficacy of intravenous anti-D in eight Rh(D)-positive women with immune thrombocytopenic purpura (ITP) during the second and third trimesters of pregnancy. The median pretreatment platelet count was 28 x 109/l. The patients received one to seven anti-D infusions at a mean dose of 62.7 micro g/kg, and the response rate to anti-D was 75%. A haemoglobin decrease of > 2.0 g/dl occurred only once. Fetal hydrops was not identified by ultrasonography. The direct antiglobulin test was positive in three out of seven Rh+ newborns, none of whom was anaemic or jaundiced. Anti-D is effective and appears to be safe for both mother and fetus.
D000328:Adult; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007262:Infusions, Intravenous; D007518:Isoantibodies / Q000008:administration & dosage*; D010865:Pilot Projects; D010976:Platelet Count; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000097:blood / Q000628:therapy*; D011262:Pregnancy Trimester, Second; D011263:Pregnancy Trimester, Third; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000097:blood / Q000628:therapy*; D012204:Rh-Hr Blood-Group System; D018029:Rho(D) Immune Globulin
D007518:Isoantibodies; C061961:RHO(D) antibody; D012204:Rh-Hr Blood-Group System; D018029:Rho(D) Immune Globulin